ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: preliminary results from a phase 1 dose expansion cohort (NCT02157792).
Authors
Telli, MLLord, S
Dean, Emma J
Abramson, V
Arkenau, H
Murias, C
Becerra, C
Tang, R
Penney, M
Pollard, J
Conboy, G
Fields, S
Shapiro, G
Tolaney, S
Affiliation
Cancer Research Stanford University School of Medicine, Stanford, CAIssue Date
2018-02-14
Metadata
Show full item recordCitation
ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: preliminary results from a phase 1 dose expansion cohort (NCT02157792) 2018, 78(4 Suppl): OT2-07-07 Cancer ResJournal
Cancer ResearchDOI
10.1158/1538-7445.SABCS17-OT2-07-07Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.SABCS17-OT2-07-07